A Phase 1a/1b Open-Label Study With Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
Latest Information Update: 20 Jan 2026
At a glance
- Drugs NXC 201 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
Most Recent Events
- 20 Jan 2026 New trial record